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Abstract
Neurological disorders are the leading cause of disability and the second largest 
cause of death worldwide. Despite significant research efforts, neurology remains 
one of the most failure- prone areas of drug development. The complexity of the 
human brain, boundaries to examining the brain directly in vivo, and the significant 
evolutionary gap between animal models and humans, all serve to hamper transla-
tional success. Recent advances in microfluidic in vitro models have provided new 
opportunities to study human cells with enhanced physiological relevance. The abil-
ity to precisely micro- engineer cell- scale architecture, tailoring form and function, 
has allowed for detailed dissection of cell biology using microphysiological systems 
(MPS) of varying complexities from single cell systems to “Organ- on- chip” models. 
Simplified neuronal networks have allowed for unique insights into neuronal trans-
port and neurogenesis, while more complex 3D heterotypic cellular models such as 
neurovascular unit mimetics and “Organ- on- chip” systems have enabled new under-
standing of metabolic coupling and blood– brain barrier transport. These systems are 
now being developed beyond MPS toward disease specific micro- pathophysiological 
systems, moving from “Organ- on- chip” to “Disease- on- chip.” This review gives an 
outline of current state of the art in microfluidic technologies for neurological disease 
research, discussing the challenges and limitations while highlighting the benefits and 
potential of integrating technologies. We provide examples of where such toolsets 
have enabled novel insights and how these technologies may empower future inves-
tigation into neurological diseases.
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1  | INTRODUC TION
Neurological disorders are estimated to be responsible for 276 mil-
lion disability- adjusted life years and 9 million deaths per year 
worldwide (Feigin et al., 2019). With an increasing incidence of 
neurological diseases over the last 25 years and an economic bur-
den of $789 billion per annum in the United States alone (Gooch 
et al., 2017), neurological disease presents a significant challenge for 
modern medicine. Despite significant research efforts, neurology 
remains one of the most failure- prone areas of drug development.
Across all disease types, as much as 90% of prospective medications 
entering clinical trials fail to reach approval (Perry & Lawrence, 2017). 
According to the 2018 Tufts Center for the Study of Drug Development 
Impact report, central nervous system (CNS) drugs take 20% longer to 
develop and 38% longer to be approved when compared to non- CNS 
drugs. Furthermore, CNS drugs show an increased probability of late- 
stage clinical trial failures (Pankevich et al., 2014). These significant 
scientific challenges faced by translational neuroscience resulted in a 
substantial drop in pharmaceutical CNS program portfolios between 
2009 and 2014, with all of the top 10 leading pharmaceutical compa-
nies reducing their CNS drug development programs over this period 
(D. W. Choi et al., 2014). Despite a recent resurgence in interest in CNS 
drugs, with regulatory bodies responding to the unmet need for new 
CNS drugs through policies to promote innovation, along with phar-
maceutical companies re- strategizing by partnering with academic in-
stitutions and small biotechnology companies, development of novel 
CNS therapeutics remains extremely challenging.
1.1 | The importance of studying human cells for 
human disease
Animal models have provided significant insights into biologi-
cal systems and are currently indispensable in the drug discovery 
pipeline, however, numerous important cellular and molecular dif-
ferences between species should not be overlooked. In the context 
of the brain, there are significant species- specific differences in ef-
flux transporters, tight junctions, and cell– cell signaling observed 
in brain endothelial cells (BECs, Warren et al., 2009), extensive in-
terspecies variation between human and rodent astrocytes (includ-
ing functional and morphological complexity, glutamate responses, 
and immune responsivity) (Chandrasekaran et al., 2016), and nu-
merous differences noted in electrical activity (Beaulieu- Laroche 
et al., 2018), gene expression and morphology (Hodge et al., 2019) 
between homologous human and rodent neurons. As such the inclu-
sion of human- derived cells, tissues, and patient samples is highly 
recommended to improve predictive power in dementia research 
(Vargas- Caballero et al., 2016). The reasons for the high failure rate 
of candidate CNS drugs are myriad, including an incomplete under-
standing of the exact mechanisms underlying human disease ham-
pering model development. However, the considerable differences 
in human and animal model's cellular and molecular neurobiology 
clearly necessitates new more physiologically relevant methods to 
study human cells, in order to more effectively explore fundamental 
mechanisms and improve drug discovery and translation.
1.2 | Limitations of current in vitro methods
In vitro systems provide the opportunity to interrogate human cell 
biology, however, many cell culture approaches rely on immortalized 
or cancerous cells grown in non- physiological environments on 2D 
substrates such as functionalized glass or plastics. While providing 
a near limitless supply of cells for high- throughput screening, trans-
formed or immortalized cell lines often show substantial drift in their 
transcriptional and epigenetic profiles over repeated passaging which 
may confound pharmacogenomics studies (Horvath et al., 2016; 
Nestor et al., 2015). Furthermore, non- physiological culture condi-
tions promote genetic adaptions, and phenotypic changes. Common 
basal media formulations, such as Dulbecco's modified eagle medium 
have been optimized for rapid cell growth, often at the expense of 
maintaining cell identity. High glucose concentrations and fetal serum 
found in these media preparations have, for example, been shown 
to promote dedifferentiation of primary cell types toward fetal- like 
phenotypes (Morris, 1962). Oxygen levels are also rarely controlled 
in standard cell culture setups, often leading to far greater oxygen 
tension than would be present in tissues, impacting upon the redox 
environment and cell metabolism (Tiede et al., 2011). Plastic and glass 
substrates furthermore provide high mechanical stiffness, in the gi-
gapascal range, while most in vivo environments are on the millipascal 
to kilopascal scale. With a growing understanding of mechanobiol-
ogy and appreciation of the influence of substrate stiffness and the 
extracellular matrix (ECM) on cell behavior appropriate cell culture 
substrates are increasingly being recognized as a major factor in shap-
ing in vitro cell phenotypes (Buxboim et al., 2010; Engler et al., 2006; 
Rauti et al., 2020). Thus, standard macroscale cell culture often fails 
to recapitulate the distinct microenvironments that constitute the 
Significance
Microfluidic technologies have enabled new opportuni-
ties across a range of scientific fields, particularly neuro-
science, where the ability to organize cells to mimic brain 
structures in vitro has provided novel insights into neuro- 
biology. Once restricted to specialist laboratories and 
cross- disciplinary collaborations, systems are now com-
mercially available and becoming an important tool in neu-
roscientist's investigational arsenal. Microfluidic systems 
are already being developed into models that recapitulate 
aspects of neurological diseases to improve drug discov-
ery. This review surmises the current state- of- the- art in in 
vitro neurological disease modeling and may serve as guide 
to those wishing to explore microfluidic toolsets to expand 
experimental possibilities.
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normal and diseased phenotypes that occur in vivo. Advances in mi-
crofluidic cell culture and “organ- on- chip” technologies have in con-
trast, allowed for an exploration of precisely tuned in vitro cell culture 
environments with greater physiological relevance.
Modeling the complexity of the human CNS in vitro, is undoubt-
edly hugely challenging. With limited ability to experimentally ma-
nipulate and probe human brains, along with translational gaps in 
animal neurological disease models, advanced microfluidic cell cul-
ture systems can serve as experimental tools to provide unique in-
sights into human cellular function in a quasi- physiological context.
2  | ADVANTAGES OF MICROFLUIDIC CELL 
CULTURE SYSTEMS OVER TR ADITIONAL 
CELL CULTURE
Microfluidic technologies provide the ability to precisely engineer 
micron to nano- scale architecture to shape the physical and chemi-
cal microenvironment, distilling brain physiology into manageable 
functional units, relevant to a specific research question (e.g., neu-
ronal circuits, blood– brain barrier (BBB) and neurovascular unit 
(NVU) models). Such microphysiological systems (MPS) have al-
ready provided unique insights into mechanisms underpinning brain 
physiology and are now being utilized to explore pathophysiological 
mechanisms and novel interventions in neurological diseases.
Microfluidic systems offer several advantages over traditional 
macroscale cell culture (for in depth reviews see (Halldorsson 
et al., 2015) and (Tehranirokh et al., 2013)). The ability to shape 
physical and chemical microenvironments with a high level of preci-
sion has allowed for new possibilities to mimic physiological environ-
ments and to manipulate and integrate different cell types (Figure 1).
2.1 | Directing cells through microphysiological 
architecture
Microfluidic devices provide a physical architecture at the cellular 
and subcellular scale, which may be used to direct, pattern or confine 
cells for the precise investigation of cell to cell interactions, parac-
rine signaling, biomolecular analysis, automated image analysis and 
axonal guidance and trafficking.
Geometries tailored for precise positioning of cells can be used 
to study contact- based signaling such as stem cell differentiation, 
myelination, immune responses, and synaptic activity. This is exem-
plified by the work of Frimat et al. in developing a single cell culture 
or co- culture microfluidic device for studying juxtracrine signaling 
(Frimat et al., 2011) (Figure 1b). By creating physical cell traps on the 
cellular scale and taking advantage of the predictable paths of fluid 
flows to direct cells, Frimat et al. achieved automated sequential po-
sitioning of cells with a 99% arraying efficiency and ∼70% pairing of 
heterotypic cells in close proximity to allow connexon interaction. 
This ability to create cell- scale architecture and precisely define 
physical barriers is especially powerful in enabling a more faithful 
representation of the spatial organization and structure of the CNS. 
Taylor et al. engineered a microfluidic multicomponent device that 
aligned the growth of neurites from a somal compartment to a neur-
ite compartment through the use of subcellular sized axon guidance 
channels, thus creating a tool to manipulate neuronal microenviron-
ments in a highly precise manner (Taylor et al., 2003). Developments 
on this device format have since been used to direct in vitro neuro-
nal connectivity and create simplified circuits to enable numerous 
biological insights as discussed later. While microfluidic device ge-
ometries can provide direct physical barriers to cells, they can also 
be used to direct flows, deposition of molecules, surface substrate 
patterning, and gel formation. For instance microfluidic devices can 
be used to create miniature stamps or templates for patterning of 
surface adhesion molecules or deposition of cells on glass coverslips 
for customized cell patterning (Chiu et al., 2000) (Figure 1c). Channel 
geometries can also pattern three- dimensional (3D) gels, taking 
advantage of surface tension to retain gels within set boundaries 
(Huang et al., 2009) (Sharma et al., 2019), or even to assemble and 
align fibrous structures of hydrogels using flows to dictate the nano-
gel structure and guide subsequent cell growth(Kim et al., 2017).
2.2 | Precise control of flow and chemical 
environment
By taking advantage of the unique physics of flow at the microscale, 
microfluidics can provide precise control of shear stress experienced 
by cells, along with chemical gradients, to mimic dynamic environ-
ments found in vivo. Microfluidic control of fluidic shear has ena-
bled new insights into mechanotransduction, for example revealing 
physical forces as a pleiotropic modulator of the endothelial cell phe-
notype, influencing BEC, tight junction expression, and transcellular 
permeability (Brown et al., 2019). Since laminar flow prevails in most 
microfluidic flow regimes, mixing is largely dictated by molecular 
diffusion, providing the possibility for spatial and temporal chemi-
cal environments within the same cell culture platform for localized 
chemical stimulation even to the scale of a single cell (Horayama 
et al., 2016). Kim et al. demonstrate the power of this capability, 
creating a fully programmable and automated cell culture array to 
test the pairwise combination of drugs at the different concentra-
tions on cell cultures grown in parallel (Kim et al., 2012) (Figure 1a), 
helping to address the challenge of scaling screening processes with 
combinatorial treatments where the availability of cells is limited, 
such as with primary cells. In the context of the CNS microfluidic 
cell culture devices have enabled production of chemical gradients 
to provide insights into microglial chemotaxis (Cho et al., 2013), 
endothelial migration, angiogenesis, and vasculogenesis (Barkefors 
et al., 2008; Kuzmic et al., 2019) and neurite outgrowth and guidance 
mechanisms (Romano et al., 2015). Microfluidic control of chemical 
milieus has also been extended to the gaseous microenvironment, 
such as oxygen levels and other bioactive gaseous compounds 
such as nitric oxide, carbon monoxide, and hydrogen sulphide (Wu 
et al., 2018). Spatiotemporal chemical control has also been achieved 
at sub- millisecond resolution and femtoliter volumes, allowing for 
the investigation of extremely fast reactions such as precise ligand 
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binding dynamics (Chiang & West, 2013) and nano/femtoliter chemi-
cal release has allowed for investigations using “artificial chemical 
synapses” (Peterman et al., 2004).
2.3 | Integration of analysis
The use of MPS provides the additional benefit of enabling inte-
gration of monitoring systems, such as transepithelial/endothelial 
resistance (TEER), impedance and electrophysiological systems. 
Such techniques often allow for real- time, long term, label- free, and 
relatively non- invasive monitoring of cell culture conditions and cel-
lular processes.
Gene expression and protein translation changes may occur on 
the scales of seconds to minutes, with phenotypic or morphological 
changes occurring on the scale of minutes to hours. Current cell as-
says are rarely capable of encompassing all of these timescales, gath-
ering continuous data that can report on cell function under different 
conditions. Organ- on- chips and MPS have the potential to push the 
boundaries of on- board sensing devices that continuously monitor cell 
metabolism, phenotype, and growth to allow collection of multipara-
metric data over hours and days if not weeks (Modena et al., 2018).
F I G U R E  1   Advantages of microfluidic cell culture systems. (a). Control of fluid flows used to provide precision cell positioning (Frimat 
et al., 2011) (image reproduced from Frimat et al., 2011 LoC with permission from The Royal Society of Chemistry). (b). Patterning of protein 
disposition on surfaces using microfluidic stenciling and transfer printing to control patterning (Chiu et al., 2000) (image adapted from Chiu 
et al., 2000 with permission from PNAS, Copyright (2000) National Academy of Sciences, U.S.A.). (c). Microfluidic systems allow for precise 
control over mixing and chemical gradients for drug screening (adapted from Kim et al., 2012 with permission from The Royal Society 
of Chemistry). (d) Physical guidance of axons through microchannels, and integration of electrodes for cell monitoring and stimulation. 
(Reproduced from Jang et al., 2016 with permission from The Royal Society of Chemistry.) (e). Integration of electrodes providing recording 
of in vitro neuronal activity at subcellular, cellular, and network level (reproduced from Müller et al., 2015 Published by The Royal Society of 
Chemistry)
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While many microfluidic chips are optically clear allowing for fluo-
rescence assays, which are increasingly becoming automated, growing 
attention has focused on electrical systems that monitor properties 
of cells in a non- invasive manner. Pioneering work by Giaever and 
Keese explored how electrical impedance spectroscopy could be 
used to measure cell adhesion, differentiation, and even micromo-
tion (Giaever & Keese, 1984; Lo et al., 1995). Further developments 
in this vein have led to devices integrated with traditional cell culture 
formats (multi- well plates and Transwell devices) for measuring TEER 
(Wegener et al., 2004). Examples of microfluidic chips with integrated 
sensing are becoming more widespread. There are two main types of 
device— those which integrate electrodes above and below cells grown 
on a porous membrane (analogous to a Transwell system) and those 
which integrate electrodes directly into the surface on which the cells 
are grown (Benson et al., 2013). In the case of the BBB, the Transwell 
device is potentially more relevant, as both the TEER of the endothelial 
cells, along with the ability of molecules to be transported across the 
barrier are interesting complementary parameters (Griep et al., 2013; 
Park, Mustafaoglu, et al., 2019). Neuronal firing can also be usefully 
interrogated using multi- electrode arrays, which pick up on action 
potentials at given frequencies. Maoz et al. have even demonstrated 
integration of both multi- electrode array and transepithelial electri-
cal resistance onto a single device for simultaneous measurements 
of cellular electrical activity and barrier function (Maoz et al., 2017). 
Although at present such arrays cannot access intercellular electrical 
activity (e.g., picked up via patch clamp), monitoring neuronal firing in 
mono- culture or even in organoids or spheroids can be extremely valu-
able for drug discovery. Given the numbers of neurons present in any 
given network, leveraging the power of microelectrode arrays (MEAs) 
within a microfluidic chip is hugely beneficial (Müller et al., 2015) 
(Figure 1d,e) particularly when coupled with the ability to accurately 
pattern and position cells (Soscia et al., 2017). For a detailed review of 
sensor integration into MPS please see Kilic et al. (2018).
3  | MICROFLUIDIC TOOL S TO STUDY 
NEURONAL FUNC TION
In recent years, microfluidic technologies have increasingly been 
used in neuroscience research, to extend the experimental capabili-
ties for studying axonal guidance and transport, synapse formation 
and function, and neuronal function across subcellular to network 
levels (Neto et al., 2016). Through precise control of microenviron-
ments, MPS offer new opportunities to create in vitro physiologically 
and pathophysiologically relevant models.
3.1 | Directing neurons: Guiding and 
compartmentalization
In 1977, Campenot et al. developed a compartmented culture sys-
tem to separate the neuronal axon from the soma. Consisting of a 
Teflon separator attached to a glass substrate, this device provided 
new possibilities to investigate various neuronal functions such as 
axonal transport and migration. However, this system had a number 
of drawbacks including: the technical difficulty of assembly and use, 
limited imaging possibilities, and leakage of media due to poor adhe-
sion of the grease seal. The crucial limitation, however, was that this 
system relied on neurotrophin gradients to direct axon growth be-
tween compartments, meaning that neurotrophin independent CNS 
neurons were not compatible, and the system was limited to periph-
eral nervous system (PNS) neurons. The advent of microfluidic de-
vices has enabled vast improvements in spatially separating neuronal 
axons and soma, allowing culture of CNS neurons through physical 
guidance in subcellular microchannels, connection of multiple com-
partments, and devices providing directional neurite outgrowth.
Based on the microfluidic design proposed in a landmark paper from 
2003 (Taylor et al., 2003), several examples of how neuronal cell cul-
tures can be grown, manipulated, and studied in microfluidic devices 
have been provided in the last 15 years, with a number of device op-
tions commercially available for neuroscientists to study axonal growth 
and connectivity, such as Merck's AXIS™ Axon Isolation Devices, 
Ananda's™ Neuro Devices, Ufluidic's Axon chips, eNUVIO OMEGA4 
Neuronal Co- Culture chips and Xona Microfluidics® XonaChips (sum-
marized in Table 1) . Various modifications of the device layout and 
the development of new methodologies based on the device topology 
have since been reported, expanding the breath of applications that 
miniaturized technologies can provide in neuroscience research, such 
as axonal response to injury (Taylor et al., 2005), myelination (Park 
et al., 2009), synaptic formation and function (Shi et al., 2013), probing 
the direct and indirect response of neuronal cultures to chemical stimuli 
(Robertson et al., 2014), neurite growth (Frimat et al., 2010) (Nagendran 
et al., 2018), proof- of- concept pharmacology (MacKerron et al., 2017), 
and drug screening (Fantuzzo et al., 2020). Microfluidic topologies have 
also shown the capability to promote the asymmetric spatial organiza-
tion of dendritic and axonal subcellular components, leading to the for-
mation of unidirectional connections where axons from one culture are 
free to grow in a permissive direction, but extension from a neighboring 
culture is impeded, thus forming asymmetric connections (Holloway 
et al., 2019). Directional neuronal connectivity is a key feature of the 
functional anatomy of the brain and in vitro models enabling asymmet-
ric neuronal patterning opens up new possibilities to mimic key regions 
of the nervous system. Microfluidic designs based on directional bias 
and axonal edge guidance have been successfully demonstrated mostly 
using rodent cultures (Holloway et al., 2019; Peyrin et al., 2011; Renault 
et al., 2016) (Figure 2a,b), and also more recently with induced pluripo-
tent stem cell (iPSC)- derived neuronal cultures (Gribaudo et al., 2019). 
Other methods to direct neuronal outgrowth include direct micro- 
manipulation (Magdesian et al., 2017) as well as use of gradients of neu-
rotrophic factors using spatio- temporal fluid control (Millet et al., 2010; 
Taylor et al., 2015) (Figure 2c). Micro- contact printing may also be used 
to pattern surface proteins promoting neuronal outgrowth in defined 
circuits (Offenhäusser et al., 2007), allowing for open top platforms, 
easy access, and integration of electrophysiological measures. Fidelity 
and longevity of the surface patterning along with conformity of cell 
growth to the exact pattern remain a drawback of this technique.
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Neural circuits have been formed in 3D hydrogels using fluid 
flows to align ECM fibers during gelation to guide axon growth. Bang 
et al. used this technique to create neuronal bundles and fascicu-
lated axons (Bang et al., 2016) while Kim et al. exploited the fibrillo-
genic properties of collagen, to create an anisotropically organized 
CA3– CA1 neural circuit (Kim et al., 2017). However, with the greater 
physiological relevance provided by directing 3D neuronal circuits, 
this also provides an added layer of complexity in probing neuronal 
function and analysis workflows.
3.2 | Electrophysiological probing neuronal function
The above outlined methods for creating neuronal circuits 
in vitro are now increasingly being integrated with MEAs for 
electrophysiological interrogation, combining the advantageous 
spatial cell patterning capabilities and precise control of chemi-
cal cues provided by microfluidics with electrical stimulation 
and recording of neuronal networks. Throughout the years, sev-
eral methodologies have been developed, from manual whole 
cell patch clamping in standard two- chamber microfluidic de-
vices (Jokinen et al., 2013), to tubeless devices based on capil-
lary forces for drug delivery (Resto et al., 2017), to microfluidic 
planar patch clamp systems (Xu et al., 2014) with automated drug 
delivery (Yuan et al., 2016). However, it is the integration of mi-
crofluidics with MEA substrates, possibly due to the planarity of 
both technologies, that has produced higher- throughput and in-
novative computational solutions. Earlier studies combined com-
mercially available MEA substrates with standard two- chamber 
devices (Kanagasabapathi et al., 2011) and lately with more 
F I G U R E  2   Methods for directing neurons and simplistic cell circuits. (a) Peyrin et al. use funnel shaped neurite outgrowth channels to 
preferentially guide axons from one chamber to the other (reproduced from Peyrin et al., 2011 with permission from The Royal Society of 
Chemistry). (b) Renault et al. exploit a prohibitive critical angle of growth to create return loops within the outgrowth channels (reproduced 
from Renault et al., 2016 with permission from The Royal Society of Chemistry). In the permissive direction the angle is too great and the 
axons predominantly continue, in the non- permissive direction axons follow the edge of the channel and are looped back. (c). Gradients 
of neurotrophic factors can be used to guide axon growth (reproduced from Taylor et al., 2015 with permission from The Royal Society of 
Chemistry). (d). Alignment of ECM fibers during gelation using flow, can be used to guide axon growth in 3D aligned bundles (reproduced 
from Bang et al., 2016 with permission from Advanced Healthcare Materials, John Wiley and Sons)
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bespoke layouts such as van de Wijdeven et al.’s device containing 
three nodes connected in series, with integrated MEA. This sys-
tem allows for measurement of extracellular electrophysiological 
activity in response to axotomy, with separate synaptic channels 
enabling mechanical shearing of axons via introduction of an air 
bubble through pipetting (van de Wijdeven et al., 2019).
3.3 | Toward networks
Neural circuits are anatomical connections within the brain 
with far- reaching implications for many neural functions. As an 
example, the hippocampus, known to be involved in spatial navi-
gation, consists of multiple sub- regions which are interconnected 
in a predefined, mostly unidirectional, way (e.g., mossy fibers) 
(Strange et al., 2014). Similarly, the midbrain is another example 
of a source of projection neurons (Caggiano et al., 2018; Tovote 
et al., 2016). Dopaminergic neurons in this area project to areas 
across the brain, including the striatum and multiple cortical areas. 
The majority of studies carried out on such specific brain regions 
have been performed ex vivo using brain slices. However, this ap-
proach has obvious limitations due to undesired axotomy, uncer-
tainty on cell topological connections and short experimentation 
times due to cell death. Therefore, in vitro models where different 
F I G U R E  3   In vitro neural networks mimicking connectivity between brain regions. (a) Kajtez et al. combine 3D printing with 
microfabrication techniques to create macro- and microscale architecture in a simplified nigrostriatal pathway using human stem cell- 
derived neurons (figure reproduced from Kajtez et al., 2020 under the terms of the Creative Commons Attribution License). (b) Samson 
et al., use a five- chamber neural guidance device to connect primary hippocampal neurons, revealing network level activity buffers against 
excitotoxicity. (reproduced from Samson et al., 2016 under the Creative Commons Attribution 4.0). (c). Soscia et al. use a removable insert to 
pattern primary rodent hippocampal and cortical neurons onto an MEA which showed characteristic bursting and communication between 
neuronal compartments (modified from Soscia et al., 2017 under the Creative Commons Attribution License)
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cell populations can be grown and connected “ad hoc” present 
simplified but valuable tools to investigate network function as 
well as neuropathological conditions. Microfluidic technologies 
have been employed to create human brain- mimicking neuronal 
circuits for the study of cortico- striatal networks using calcium 
imaging (Lassus et al., 2018), to model neuroprotective mecha-
nisms (Samson et al., 2016), to study structure– function relation-
ship by precise neurite guidance achieved by electric fields [77]), 
to highlight brain region- specific cell identities (Kamudzandu 
et al., 2019), physiology and function (Dauth et al., 2017), to cre-
ate 3D structured circuits (van de Wijdeven et al., 2018) and for 
drug screening (S. R. Lee et al., 2019) (Figure 3). Kajtez et al., have 
also recently used a hybrid fabrication technique by integrating 
3D printing with soft lithography to provide rapid prototyping at 
both micro- and macroscale, enabling open- well compartmental-
ized devices with greater freedom of device design (Figure 3a) 
(Kajtez et al., 2020). Using this system, they demonstrate a proof- 
of- principle human in vitro model of the nigrostriatal pathway 
using human stem cell- derived neurons (Kajtez et al., 2020). Such 
advancements in device fabrication techniques could in future be 
utilized to create more physiologically relevant neural network mi-
metics of key pathways to interrogate network level connectivity 
in pathophysiological contexts.
4  | HETEROT YPIC CELL CULTURE 
SYSTEMS: TOWARD ORGAN-  ON-  CHIP 
MODEL S
Historically, the neuron has provided the central focus for studies 
of neurological diseases. Recent years have, however, seen a con-
ceptual shift from this neuro- centric view to one that emphasizes 
the importance of multidirectional interactions between all brain cell 
types, including neurons, glia, vascular, and perivascular cells. This 
concept of the NVU, (formalized at the 2001 NINDS Stroke Progress 
Review Group meeting) has emerged as a new paradigm from which 
to investigate brain physiology and pathobiology and has revealed 
commonalities of pathogenic processes across many neurological 
diseases, such as glial activation and BBB compromise. As such, nu-
merous efforts have been made to replicate the heterotypic cellular 
interactions and physio- chemical environment that underpin the 
BBB and NVU in vitro, to enable a greater insight into neurological 
diseases.
4.1 | Blood– brain barrier models
The BBB is a dynamic and highly selective conduit that maintains 
the unique chemical environment of the brain (Langen et al., 2019). 
This barrier provides a considerable obstacle in delivering neuro- 
pharmaceuticals to the brain, while its disruption has been impli-
cated in the pathophysiology of a number of diseases, including 
Alzheimer's, multiple sclerosis, epilepsy, stroke, and Parkinson's 
disease. Early attempts to replicate this structure in vitro involved 
the culture of BECs on Transwells™ under static conditions to allow 
the study of transcellular and paracellular permeability. Such sys-
tems have since allowed for a dissection of the components that 
make up the BBB providing an insight into the roles of astrocytes, 
pericytes, and the ECM in BBB maintenance. While the mainstay for 
such investigations has been traditional Transwell assays, microflu-
idic technologies are now emerging that provide a greater level of 
control over microscale architecture and physiochemical cues, such 
as flow, that regulate BBB function.
The significance of the in vivo microenvironment in maintaining 
BEC properties was highlighted by observations that proliferating 
rat cerebral capillary fragments gave rise to confluent monolayers 
ex vivo but their endothelial characteristics were lost over time in 
culture (Panula et al., 1978). Early blood– brain interphases were 
generated by co- culturing primary BEC and brain parenchymal 
cells, often from different species, in different configurations on 
Transwells, with endothelial cells (ECs) suspended on membranes 
that represent an artificial barrier, typically thick (10– 50 μm) rigid 
substrates with pores (0.4– 3 μm diameter) (Figure 4a). These mod-
els helped to show that ECM composition, pericytes, astrocytes, 
or their conditioned media upregulated tight junction protein 
(TJP), polarized apico- basal transporter expression, and increased 
TEER (Abbott et al., 2006; Nielsen et al., 2017). Such transwell 
models have enabled high- throughput pharmacokinetic, pharma-
cological, and drug toxicity applications, but fail to recapitulate 3D 
BBB architecture, wall shear stress (WSS) and have a high media 
to cell ratio which dilutes paracrine signaling, thus limiting their 
translation to human BBB studies.
MPS have recently enabled dynamic neurovascular microenvi-
ronments to be precisely defined, sampled, and manipulated, while 
maintaining paracrine and juxtracrine signaling at their interphases 
(Lee & Leong, 2020). A number of approaches have been made to 
recapitulate the BBB (Figure 4b– e), each with their own benefits and 
limitations which should be considered with respect to the intended 
study (for a detailed discussion of the parameters which can be used 
to benchmark in vitro BBB models see DeStefano et al., 2018). Multi- 
layered microchambers separated by porous membranes (Figure 4b) 
such as the bi- layered Emulate chip (Table 1) enable transwell- like 
connectivity with improved compatibility with microscopy tech-
niques, while also allowing for perfusion to recapitulate vascular WSS 
(Griep et al., 2013; van der Meer et al., 2010). Compartmentalized 
membrane- based devices allow for easy sampling of vascular and 
parenchymal compartments while also enabling integration of elec-
trodes to monitor TEER. Griep et al. demonstrated the dynamic and 
responsive nature of this barrier with the introduction of flow and 
WSS increasing TJP expression and elevating TEER by a factor of 3, 
while addition of inflammatory mediators disrupted barrier function, 
reducing TEER by a factor of 10 (Griep et al., 2013). Ahn et al. incor-
porate a 3D culture in the lower pericyte/astocyte chamber, with 
flow maintained over the apical EC monolayer, showing co- culture 
to upregulate endothelial expression of TJP and membrane trans-
porters and receptors (Ahn et al., 2020). Using this model Ahn et al. 
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were able to study receptor- dependent transcytosis of nano- particle 
coupled drug delivery (Ahn et al., 2020).
Compartmentalized models with BEC monolayers are disadvan-
taged by artificial barrier interphases that limit direct neurovascular 
coupling. These systems often consist of cell monolayers that do not 
recapitulate 3D ECM and heterotypic cell interactions, also using 
rectangular channel cross sections that result in poor cell coverage 
and flow dead zones at the corners. Other microfluidic designs have 
focused on recapitulating the 3D NVU architecture to preserve 
cell associations by using cells embedded in gels. One approach to 
compartmentalize a 3D matrix has been through the use of surface 
tension to pin a gel at a change in channel geometry such as with 
phase guides or micropillars (Figure 3c), as incorporated in the Syn- 
BBB, B3C BBB models, or the commercially available MIMETAS 
OrganoPlate® (Table 1). These allow for the controlled dimensions 
of the vascular channel to be maintained while allowing 3D culture 
F I G U R E  4   Approaches to NVU and BBB models. (a) Macroscale approaches to developing BBB models typically consist of cell 
monolayers (left) and Transwell systems (center and right), the relatively low surface area to volume ratio (typically ~10 cm−1) can result in 
poor gas exchange and distance between heterotypic cells can result in a large dilution of paracrine signaling factors. Microfluidic systems 
typically have surface area to volume ratios of ~800 cm−1 and show rapid gas exchange, however, rapid accumulation of waste products 
and consumption of nutrients necessitates flow. Multiple approaches to dynamic microfluidic BBB models have been made. (b) Two layer 
systems, utilize a membrane to separate blood and brain compartments, such as in the Emulate chip, similar to a transwell system but 
incorporating flow and with more physiological cell- extracellular fluid ratios. (c). Devices using pillars or phase guides on one edge (as in 
the Mimetas OrganoPlate®, the SyM- BBB (Prabhakarpandian et al., 2013) and SynVivo's SynBBB) pin a cell laden gel allow for a lumen with 
one region in direct contact with parenchymal cells in 3D. (d). Fully 3D defined lumens can be created in a gel using sacrificial (Golden & 
Tien, 2007) or removable moulds (Bouhrira et al., 2020) or by taking advantage of Saffman– Taylor instability such as (Herland et al., 2016). 
These create relatively large (100– 300 μm) lumens in straight channels allowing for direct cell– cell contact. (e) Pinning cell laden gels to a 
central channel and creating a gradient of pressure or growth factors can be used to stimulate vasculogenesis and create perusable capillary 
like networks of physiologically relevant sizes with direct contact between parenchymal and vascular cells as in AIM Biotech chips
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and direct contact with perivascular cells and astrocyte endfeet. 
BBB permeability and transcellular flux can be assessed by live im-
aging of fluorescent molecules of different sizes and properties. 
Using the B3C BBB chip (Figure 4c) Deosarkar et al., show that such 
an approach results in significantly improved barrier characteristics 
when directly compared to transwell models using the same cells, 
to values that approach those found in vivo (Deosarkar et al., 2015) 
(Figure 5c).
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Using the above approach only one side of the vascular chan-
nel is in contact with the parenchyma. To address this, researchers 
have utilized the phenomenon of viscous fingering by which a flow 
of a lower viscosity fluid can replace a denser one, in this case a 
hydrogel, to create a fully circular cross- section lumen (Figure 4d). 
Herland et al., utilized this approach to uncover distinct contribu-
tions of astrocytes and pericytes to BBB inflammatory responses 
(Herland et al., 2016) (Figure 5d). De Graaf et al. have since refined 
this technique, demonstrating scalability for production of blood 
vessel models (de Graaf et al., 2019). Other approaches to forming 
circular lumens, have been through sacrificial moulds or removable 
templates, providing more flexibility in vessel geometries, allowing 
investigation of disturbed flows at vessel bifurcations on BBB in-
tegrity (Bouhrira et al., 2020). More recently, this approach has also 
been used to demonstrate that severe acute respiratory syndrome 
coronavirus 2 spike protein alters barrier function (Buzhdygan et al., 
2020). These approaches are limited in that they produce relatively 
large diameter lumens compared with the brain capillaries of the 
BBB which does not allow the complete ensheathment of the vascu-
lature with pericytes or astrocyte endfeet as occurs in vivo.
Cellular self- organization has also been utilized for the produc-
tion of 3D networks (Figure 4e). By confining a hydrogel to a re-
gion flanked by perfusion channels, gradients of growth factors 
or fluid flow can be used to stimulate vasculogenesis or angiogen-
esis through the gel (Figure 5e,f). Such models produce vessels 
highly similar to in vivo vascular beds, although they often require 
support from fibroblasts to allow lumen formation and vessel sta-
bilization. Campisi et al. have, however, recently been able to suc-
cessfully produce luminized vessels by co- culturing hiPSC- BEC with 
human primary brain pericytes and astrocytes (Figure 5f) allowing 
pericytes and astrocytic end feet to directly contact the perfused 
vascular network (Campisi et al., 2018). This model recapitulated 
physiological permeability coefficients and preserved intra- luminal 
mechanotransduction. Such platforms are well suited to studies of 
vasculogenesis, vascular remodeling, and could be used in conjunc-
tion with iPSC technologies to study the effect of genetics on vessel 
formation, such as cerebral autosomal dominant arteriopathy with 
subcortical infarcts and leukoencephalopathy. Homogenous WSS 
or TEER measurements are, however, difficult to achieve due to the 
unpredictable geometry of vessels formed.
4.2 | Neurovascular unit models
The NVU represents a functional unit of the brain. By extending 
BBB models to include neurons, microfluidic in vitro systems have 
been able to better model the NVU, demonstrating physiologically 
relevant BBB integrity, cell– cell interaction and paracellular signaling 
and metabolic coupling.
Maoz et al. demonstrate the power of utilizing BBB chips with 
neuronal culture by connecting a BBB chip to an hES- derived neu-
ronal culture upstream of a second BBB chip. This enabled influx of 
perfused metabolites to be traced across the BBB, through neuronal 
compartment and efflux out of the second BBB chip, to show that 
metabolites produced by the endothelium and cells of the perivas-
cular niche directly influence GABA and glutamatergic neurotrans-
mitter synthesis within the brain compartment, thus identifying a 
previously unknown metabolic coupling between BBB and neu-
rons(Maoz et al., 2018) (Figure 5b).
Bang et al. take a vasculogenesis approach, culturing HUVECs 
in a central fibrin gel channel flanked by a vascular channel and 
neuronal/astrocyte co- culture channel. This allows the formation 
of capillaries in direct contact with astrocytes and neurons, while 
separate channels enabled media to be optimized for each culture 
(Bang et al., 2017) (Figure 5e). This approach, however, required an 
additional culture channel containing lung fibroblasts which contin-
ually condition the media to support HUVEC vessel formation. The 
use of brain resident vessel support cells, such as pericytes, could 
be used in future to negate the need for non- brain resident cells.
Adriani et al. employed micropillars to pattern two distinct cell 
laden hydrogels of neuronal and astrocyte cultures with a third 
channel being lined with human BECs to form the BBB interphase 
(Adriani et al., 2017). This model displayed size- selective barrier per-
meabilities and an active neuronal network. While the permeability 
coefficients were supraphysiological, likely due to combining cells 
from different species and the absence of pericytes, it provided 
functionally coupled 3D NVUs for assessing the effects of perfused 
drugs on neuronal activity. A subsequent brain- on- chip model inte-
grated human ES- derived motor neuron spheroids with iPSC- BECs 
in a common collagen gel, revealing BEC to promote neuronal con-
nectivity and increase synchronized activity through paracrine and 
contact- dependent signaling (Osaki et al., 2018).
F I G U R E  5   Microfluidic BBB and NVU models. (a) Park et al. use an Emulate two layer chip to co- culture iPSC derived human brain 
endothelial cells with primary human brain astrocytes and pericytes suspended on a membrane (modified from Park, Mustafaoglu, 
et al., 2019 under the creative commons license 4.0). (b) By utilizing multiple connected chips as a full NVU model, incorporating endothelial 
lined channels separated by a membrane from an astrocytes/pericyte co- culture that links to a neuron/astrocyte culture, Maoz et al. (2018) 
were able to study metabolic fluxes and interactions across the NVU. (c) Deosarkar et al.’s B3C BBB chip (now commercially available as 
Synvivo's SynBBB) uses micropillars to pin a gel to a central region allowing 3D culture of astrocytes with endothelial cells in the surrounding 
channel (adapted from Deosarkar et al. (2015) 2015 PLOS ONE under the Creative Commons Attribution License). (d) Herland et al., take 
advantage of Saffman– Taylor instability by using fluid flow to displace collagen during gelation, creating a circular lumen for use as a 3D BBB 
model (Herland et al., 2016). (e) Bang et al. use vasculogenesis through a central gel pinned by surface tension to develop an NVU model 
with neurons astrocytes and endothelial cells, supported by fibroblast derive factors released from a separate fibroblast compartment 
(reproduced from Bang et al., 2017 under the Creative Commons Attribution 4.0 International License). (f) Campisi et al. use a similar 
technique to provide a human BBB model with endothelial cells, pericytes and astrocytes (reproduced from Campisi et al., 2018)
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More recently, iPSC technologies have been used in the Emulate 
dual compartment chip to create isogenically derived human iPSC- 
NVUs to provide a platform for studying personalized medicine and 
patient- specific disease (Vatine et al., 2019). This model demon-
strated physiologically relevant TEER (>1,000 Ω/cm2) and could 
appropriately distinguish between substances of known in vivo 
BBB permeabilities, while also protecting neural cells from plasma- 
induced toxicity upon whole blood perfusion. Two NVU disease mod-
els were generated using hiPSC- derived from Huntington's disease 
patients, or by using Crispr/Cas9 to modulate the monocarboxylate 
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transporter 8 (MCT8) transporter as a model for MCT8 deficiency, 
a severe form of psychomotor disability, both showing appropriate 
disruption of barrier integrity. Paving the way for full NVU models 
of human disease.
5  | MICROFLUIDIC MODEL S OF 
NEUROLOGIC AL DISE A SES
5.1 | Alzheimer's disease
The past three decades, have shown great advances in the under-
standings of the cellular and molecular events underlying Alzheimer's 
disease such as the aberrant accumulation of amyloid- β (Aβ) and the 
hyperphosphorylated microtubule- associated protein Tau. Exact 
pathological mechanisms of initiation and progression remain un-
clear and have hampered disease modeling and development of ef-
fective treatments. Of more than 400 trials in humans, no disease 
modifying drugs have yet made it to the market.
In recent years microfluidic devices have enabled new insights 
into the trafficking and accumulation of pathological Aβ and tau in 
human cells.
Using microfluidic devices, several studies have analyzed the dif-
ferent species that can propagate from cell to cell. Tau dimer, trimer, 
or oligomer aggregates as well as short fibrils, but not monomers or 
long fibrils, can be taken up by neurons and transported both an-
terogradely and retrogradely (Usenovic et al., 2015; Wu et al., 2013). 
Tau oligomers, but not monomers, also induce an increase in aggre-
gated and phosphorylated Tau, alongside neurite retraction, loss 
of synapses, aberrant calcium homeostasis, and imbalanced neu-
rotransmitter release (Usenovic et al., 2015). Another study shows 
that phosphorylated high- molecular- weight Tau, although very 
low in abundance, is taken up, transported in axons, and transmit-
ted through synapses to connected neurons (Takeda et al., 2015). 
Tau pathology is propagated via synaptic activity (Wu et al., 2016), 
possibly through exosomes (Wang et al., 2017), as well as non- 
synaptic mechanisms (Calafate et al., 2015). Studies using MPS have 
contributed to elucidate the prion- like propagation of Tau, and to 
clarify tau species involved and effects on recipient cells (reviewed 
in (Hallinan, Pitera, et al., 2019)) and have more recently been used to 
screen Tau targeted prospective therapeutics. Using a three cham-
ber MPS Nobuhara et al. showed that some Tau antibodies, targeting 
the protein mid- domain, efficiently blocked the Tau uptake, aggrega-
tion, and spreading (Nobuhara et al., 2017).
There is also accumulating evidence of trans- synaptic transmis-
sion of Aβ. Song et al. showed Aβ absorption by axonal processes 
and retrograde transport (Song et al., 2014), Using a microfluidic- 
based reconstructed neuronal network, Deleglise et al. showed Aβ 
induces a dying- back process and synaptic alterations in presynaptic 
neurons, as well as hyperphosphorylated Tau in postsynaptic neu-
rons (Deleglise et al., 2014). By creating an MPS generating spatial 
gradients of diffusible oligomeric assemblies, Choi et al. found Aβ 
exposure produced an atrophy effect on neurons cultured under 
continuous flow (Choi et al., 2013).
Use of 3D cultures, closer to the in vivo physiology, allows more 
authentic recapitulation of molecular and cellular events under-
lying Alzheimer's disease. The first 3D culture to model formation 
of both Aβ plaques and hyperphosphorylated tau tangles was pub-
lished in 2014 (S. H. Choi et al., 2014). Since then, other examples 
of 3D cultures analyzed the role of Aβ secretion and accumulation 
(Papadimitriou et al., 2018; Pavoni et al., 2018). Advantages and lim-
itations of these 3D models are reviewed elsewhere (Siney et al., 
2018). Nonetheless, combining these powerful 3D models with mi-
crofluidic platforms allows new opportunities to model aspects of 
the disease beyond a neurocentric viewpoint. The role of microglia in 
Alzheimer's disease has been widely documented for several years. 
MPS have allowed exploration of microglial responses to Aβ gradi-
ents (Cho et al., 2013), as well as microglia recruitment or neuron– 
astrocytes interactions in a ground breaking 3D human Alzheimer's 
disease tri- culture model (Park et al., 2018) (Figure 6). BBB dys-
function is a well- known aspect of the disease. Shin et al. recently 
used a microfluidic model of the BBB to study the influence of Aβ 
on BBB phenotype. By incorporating 3D culture of human neural 
progenitors with mutations in the amyloid precursor protein gene, 
F I G U R E  6   Microfluidic models amenable to neurological disease modeling. (a). Use of a three chamber axon guidance microfluidic 
device to study TauE14 (green) axonal transport, prion seeding and native Tau (red) aggregation (modified from Hallinan, Vargas- Caballero, 
et al., 2019 used under CC- BY). (b). A 3D human tri- culture model of Alzheimer's disease demonstrating Aβ aggregation, phosphorylated tau 
accumulation and microglial recruitment (adapted by permission from Springer Nature: Park et al., 2018). (c) Microfluidic methods such as 
those by Menon et al., might be used for stroke studies. Here air pressure under a flexible membrane is used to induce controllable vessel 
stenosis to study leukocyte- endothelial interactions in atherosclerosis (adapted from Menon et al., 2017 (Venugopal Menon et al., 2018) 
under the CC BY license). (d) Microfluidic methods such as demonstrated by Lo et al., (Chen et al., 2011) can create spatially defined oxygen 
concentrations which might be used to study pathogenic events in the penumbra in stroke (adapted from Lo et al., 2010 (Chen et al., 2011) 
with permission from the Royal Society of Chemistry). (e) Parkinson modeling has focused on studying the pathogenic potential of α- syn. 
By utilizing pneumatic valving, Fernandes et al., created individually addressable chambers which can be linked to allow diffusion of α- syn 
between chambers to study neuronal transmission and microglial responses (adapted from Fernandes et al., 2016 under the terms of the CC 
BY). (f). Prots et al. developed a model using iPSC derived neurons and astrocytes from Parkinson's patients, using an axon guidance device 
they demonstrate disrupted axonal transport as shown by mitochondrial kymographs (adapted from Prots et al., 2018 under the terms 
of the CC BY). (g,h) While modeling of MS using in vitro microfluidic modeling is in its infancy, various models have demonstrated in vitro 
myelination. Hyung et al. provide a 3D myelination model neurons guided using an aligned cross- linked hydrogel and optogenetic stimulation 
of myelination (adapted from Hyung et al., 2019 Biotechnology and Bioengineering with permission from John Wiley and Sons). (h) Lee et al. 
use subcellular electrical stimulation to enhance in vitro myelination of axons by oligodendrocytes in an axon guidance microfluidic device 
(adapted from Lee et al., 2017 under the terms of CC BY 4.0)
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the authors were able to replicate robust extracellular deposition 
of amyloid plaques which lead to neurofibrillary tangle formation 
and subsequent tauopathy. This system also showed increased BBB 
permeability, decreased expression of TJPs, and increased reactive 
oxygen species, thus recapitulating several key aspects of BBB dys-
function observed in Alzheimer's disease patients (Shin et al., 2019). 
Others have used MPS to demonstrate that Alzheimer's patients’ 
serum can result in vascular dysfunction (Bersini et al., 2020) and to 
gain insights into cerebral amyloid angiopathy and vascular Aβ trans-
port (Robert et al., 2017).
Such MPS, while still in development, are already being used to 
understand Alzheimer's disease pathophysiology at the molecular, 
cellular, and network level that could previously only be examined in 
large- scale animal studies.
5.2 | Stroke
Stroke, caused by a disruption of blood flow to the brain, is the 
largest cause of adult disability. However, despite significant re-
search efforts, with over 1,000 neuroprotective therapies tested 
pre- clinically, no neuroprotective treatment has yet been approved 
(O'Collins et al., 2006). Despite significant differences between 
human and rodent metabolic rates, inflammatory responses and 
neurobiology, methods to test stroke therapeutics using human 
cells are extremely limited; a 2012 literature search by Antonic et al. 
found only 30 of 30,000 stroke studies identified, used human in 
vitro models (Antonic et al., 2012). Current in vitro models of stroke 
largely consist of oxygen– glucose deprived media applied homog-
enously over a cell culture. Such models fail to replicate the focal 
injury experienced in the majority of ischemic strokes, and are often 
performed on a single cell type, thus omitting the heterotypic inter-
actions that underlie many of the pathological mechanisms in stroke.
A number of MPS have been developed that allow for precise 
temporal and spatial control of oxygen (O2) levels, even allowing for 
different shapes of gradient within the same cell culture chamber 
(Oppegard et al., 2009; Polinkovsky et al., 2009). Mauleon et al. 
have used such techniques to apply an O2 gradient over brain slices 
(Mauleon et al., 2012). By bathing hippocampal slices in artificial 
cerebrospinal fluid in an open top microfluidic perfusion device, 
Mauleon and colleagues spatially controlled localized O2 delivery 
with a resolution of 500 µm. Using this technique hypoxic insults are 
specifically delivered to either the dentate gyrus or the CA1 hippo-
campal regions across the full 350 µm thickness of the slice, while 
using fluorescent imaging to visualize real- time calcium responses. 
In future, such techniques could be used to delineate the cellular 
and molecular mechanisms that confer selective neuronal vulner-
ability of human hippocampal CA1 neurons observed in stroke 
(Bartsch et al., 2015) to potentially reveal novel therapeutic targets. 
Many of these microfluidic systems rely on the gas permeability 
of polydimethylsiloxane (PDMS) cell culture devices and complex 
switching of compressed gas supplies, requiring specialist setups. 
More recently, Sun et al., and Sleeboom et al., have demonstrated 
O2 control using O2 consuming or producing chemical reactions, in 
aqueous flow channels that run in close proximity to the cell culture 
channel. This enables control of O2 gradients in a significantly sim-
plified setup (Sleeboom et al., 2018; Sun et al., 2018). Such systems 
have not yet been applied to model stroke.
In addition to providing controlled hypoxia, microfluidic devices 
have also allowed for more detailed study of specific pathological 
processes that underlie the delayed and progressive neuronal dam-
age which follows cerebral ischemia. Initial energy crisis results in 
loss of ionic gradients and depolarization leading to excessive re-
lease of excitatory amino acids, particularly glutamate, termed exci-
totoxicity. This initiates a plethora of downstream events, including 
calcium- dependent activation of death pathways and oxidative 
stress, which work synergistically to drive neuronal death. To model 
these events in vitro, spatially defined and compartmentalized sys-
tems are required. Samson et al., have recently used microfluidic 
devices to culture environmentally isolated but synaptically con-
nected hippocampal neurons to deliver a localized excitotoxic insult. 
Using a five compartment device, Samson et al., were able to repli-
cate secondary spreading toxicity following glutamate exposure to 
one of the compartments and demonstrate a previously unknown 
innate GluN2A- dependent neuroprotective signaling that rapidly 
quenches excitation within a neural network (Samson et al., 2016). 
Similarly Hernández et al., used glutamate- induced excitotoxicity in 
a compartmentalized microfluidic neuronal circuit to study axonal 
degeneration, showing co- activation of two independent degener-
ative mechanisms in axon and soma, with axonal degeneration pro-
gressing via necroptotic kinases RIPK1 and RIPK3, while apoptotic 
events predominate in the soma (Hernandez et al., 2018). The use of 
microfluidic neuronal circuits consisting of multiple neuronal types, 
such as that presented by Kamudzandu et al. which mimics the cir-
cuitry of the basal ganglia, may further shed light on the influence of 
excitotoxity on network activity (Kamudzandu et al., 2019).
Such studies have proven highly useful in dissecting neurotoxic 
events in the context of connected networks and may help to unveil 
new therapeutic approaches to stroke treatment. NVU disruption is 
a key feature in the pathogenesis of stroke and as microfluidic mod-
els of the NVU improve, their application to stroke research may also 
provide an invaluable tool in dissecting human NVU pathobiology. 
Vascularized microfluidic systems have already been utilized to study 
thrombosis, thrombolysis, endothelial inflammatory activation in em-
bolic occlusion (Nemcovsky Amar et al., 2019), and leukocyte recruit-
ment in arteriosclerosis under defined shear rates (Costa et al., 2017; 
Herbig et al., 2018; Loyau et al., 2018; Venugopal Menon et al., 2018). 
Application of such techniques in human NVU models could provide a 
powerful investigational tool in studying disruption of neurovascular 
coupling and the development of new therapeutic strategies for stroke.
5.3 | Parkinson's disease
Parkinson's disease (PD) is a neurodegenerative disorder affecting 
over 6 million people worldwide (Dorsey et al., 2018), characterized 
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by loss of dopaminergic neurons in the substantia nigra involving the 
accumulation of intracellular protein inclusions comprised largely of 
alpha- synuclein (α- syn). Whist the exact mechanisms of PD remain 
to be fully understood, microglia activation, mitochondrial dysfunc-
tion, oxidative stress, and chronic neuroinflammation have all been 
demonstrated to play pathological roles (Dexter & Jenner, 2013). 
Toxin- based models of PD replicate many of the known mechanisms 
of cell death, however, the progressive nature of the disease and do-
paminergic selectivity is not mirrored. Drugs that have proved suc-
cessful in combating toxin- induced cell death have yet to translate 
into neuroprotective therapies for PD. Genome- wide association 
studies have informed the design of genetic models of PD, however, 
there are as yet no animal models that fully recapitulate PD pathol-
ogy (Dexter & Jenner, 2013). While a current lack of in- depth mecha-
nistic understanding of the human disease pathobiology hinders in 
vitro modeling, microfluidic systems have been used to allow inter-
rogation of specific pathological events that characterize the human 
disease.
While some studies have used MPS to explore neurotoxin mod-
els of PD, such as concentration gradients of 6- hydroxydopamine 
(Seidi et al., 2011), the main focus of microfluidic systems has 
been in building a more detailed understanding of α- syn inclu-
sion formation and trafficking, through taking advantage of 
precise control over chemical environments and compartmen-
talized cultures. Perrino et al. have used an automated microflu-
idic platform to precisely regulate α- syn levels over yeast cells, 
revealing the dependence of inclusion formation on concentra-
tion (Perrino et al., 2019), while the use of yeast cells provides a 
high- throughput assay, physiological relevance is limited. Others 
have since used human dopaminergic neurons in compartmental-
ized culture to demonstrate that uptake of exogenously adminis-
tered oligomeric misfolded α- syn and α- syn fibrils can occur both 
through the axon and soma. Transport can be either anterograde 
or retrograde, with retrograde transport found to be almost twice 
as efficient as anterograde transport (Brahic et al., 2016; Freundt 
et al., 2012). Gribaudo et al. have additionally studied the influ-
ence of two structurally and functionally distinct α- syn forms, 
fibrils, and ribbons, on human neuronal function. Both forms 
were transported, between neurons and elicited endogenous α- 
syn aggregation, disrupting synaptic integrity and mitochondria 
morphology, with ribbons bearing a more potent seeding activity 
(Gribaudo et al., 2019). Prots et al. further demonstrate the patho-
logical role of α- syn using iPSC- derived neurons from a PD patient 
carrying an α- syn gene duplication. Using a commercially available 
microfluidic axon guidance device from Xona Microfluidics, Prost 
et al. show that increased α- syn oligomers disrupt axonal integ-
rity and impair axonal mitochondrial transport (Prots et al., 2018). 
Other microfluidic systems have been used to investigate the 
interplay between different cell types under pathological condi-
tions. Fernandes et al. developed a microfluidic platform with two 
cell culture chambers connected by three channels and equipped 
with integrated pneumatic valves for precise temporal control of 
cell treatment and diffusion or perfusion between compartments. 
Using this system Fernandes et al. were not only able to observe 
the release and spread of GFP tagged α- syn between H4 neuro-
glioma cells, but were able to co- culture with N9 microglial cells 
demonstrating increased levels of reactive oxygen species in H4 
cells cultured in the presence of activated N9 cells (Fernandes 
et al., 2016). While such systems predominantly use 2D cultures 
it is increasingly being recognized that 3D architectures are re-
quired to recapitulate in vivo like gene expression profiles (Baker 
& Chen, 2012) and to reproduce more physiological equilibration 
and transport of soluble factors (Ramanujan et al., 2002). Using 
iPSC- derived dopaminergic neurons expressing the most common 
pathogenic mutation causing autosomal dominant PD (LRRK2- 
G2019S) Bolognin et al. were able to show, using the Mimetas 3D 
cell culture OrganoPlates, that in the absence of stressors, 2D cell 
culture systems fail to exhibit robust endophenotypes (Bolognin 
et al., 2018). In 3D cultures of LRRK2- G2019S neurons, compared 
to isogenic wild- type lines, showed time- dependent dopaminergic 
degeneration, altered mitochondrial morphology, and enhanced 
cell death all in the absence of exogenously administered stressors 
(Bolognin et al., 2018). Such high- throughput 3D assays may thus 
allow for more effective screening of therapeutics for PD.
5.4 | Multiple sclerosis
Multiple sclerosis (MS) is a chronic inflammatory demyelinating 
disease affecting more than 2 million people worldwide (Wallin 
et al., 2019). Commonly used experimental systems to study MS 
include neuro- inflammatory animal models such as experimental 
autoimmune encephalomyelitis, viral induced demyelination and 
inflammation, and toxin- induced demyelination such as cuprizone 
treatment. While neuro- inflammatory models reproduce the wide-
spread inflammatory features of MS, toxin- based models are more 
suited to dissect specific mechanisms of demyelination (Hooijmans 
et al., 2019). The lack of separation between neurons and myelinat-
ing cells in traditional cell culture systems has hampered the detailed 
mechanistic study of myelination and myelin maintenance in vitro. 
Microfluidic solutions for the spatial organization of multiple cell 
types in culture, are now being applied to enable more effective in-
vestigation of events underpinning MS.
Groups including Ristola et al. and Kerman et al. have provided 
improvements over traditional primary rat dorsal root ganglion 
neuron– oligodendrocyte co- culture methods, by using microchan-
nels to guide axons from one microfluidic compartment into a sep-
arately addressable oligodendrocyte compartment, resulting in the 
aligned deposition of myelin segments, thus enabling precise study 
and manipulation of myelination and demyelinating events (Kerman 
et al., 2015; Ristola et al., 2019). Vaquié et al. build upon this tech-
nique by perturbing the system using laser axotomy in both PNS and 
CNS models (using Schwann cells or oligodendrocytes, respectively) 
(Vaquié et al., 2018). As found in vivo Vaquié et al. observed that 
the PNS model recapitulates regeneration processes of Schwann cell 
de- differentiation, axonal regrowth, and remyelination over similar 
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time scales to those observed in vitro, while CNS oligodendrocytes 
remain inactive or die after laser axotomy, replicating the limited 
regenerative capacity seen in vivo. More recently Licht- Mayer et al. 
used an axonal guidance device as a model of demyelination using a 
co- culture of neurons with oligodendrocyte precursor cells and in-
ducing demyelination by exposing the axonal compartment to lyso-
lecithin, (which is similarly used in animal models of demyelination). 
Licht- Mayer et al. used this system to help uncover a novel process 
in which mitochondria move from the neuronal cell body to the de-
myelinated axon, increasing axonal mitochondrial content, and that 
enhancing this process protects acutely demyelinated axons from 
degeneration (Licht- Mayer et al., 2020). Understanding such mecha-
nisms of protection may have profound future implications for treat-
ment of MS.
Although only to date performed in a Schwann cell model, Hyung 
et al. have extended in vitro myelination models into 3D. By using 
compartmentalized system with a hydrogel pinned to a central region 
by an array of micropillars separating two main cell culture channels 
they demonstrate that optogenetic neuronal stimulation promotes 
axon outgrowth and myelination (Hyung et al., 2019). Stimulation 
produced longer axons and increased the thickness of the myelin 
sheath to levels more comparable to in vivo estimates. Yang et al. 
replicate this activity dependent myelination using a microfluidic 
device with integrated platinum electrodes for biphasic electrical 
stimulation of cultures (Yang et al., 2012). Such studies highlight 
the importance of not only mimicking the physical structure and 
microenvironment to improve physiological relevance but also that 
relevant electrochemical stimulation may provide more in vivo like 
responses. While such devices have not yet been used to specifi-
cally model MS, the recapitulation of myelinating and demyelinating 
events achieved in such systems provides a great opportunity to in-
troduce toxins traditionally used in MS modeling, or activated T cells 
to perturb the system to investigate potential therapies to promote 
demyelination and neuronal survival.
Understanding the migration characteristics of immune cells 
derived from cerebrospinal fluid of MS patients represents another 
challenge to which microfluidic in vitro systems are ideally suited 
and this is now being pursued by a number of research groups. 
Chemotaxis devices have allowed for the study of primary human T 
cell and dendritic cell migration to both soluble and matrix immobi-
lized chemokine gradients such as CXCL12, a chemokine found to be 
increased in the cerebrospinal fluid of MS patients, and both CCL19 
and CCL21 chemokines which are increased in the CNS of experi-
mental autoimmune encephalomyelitis models of MS. In a device by 
Mehling et al. a gradient of CXCL12, was established by switching of 
a source- sink flow using integrated microfluidic valves. Multiple inlet 
and outlet channels along the path of the gradient, perpendicular to 
the gradient, allow for the initial positioning of T cells and their sub-
sequent retrieval, through different channels based on how far they 
migrate along the gradient (Mehling et al., 2015). This system allowed 
for the division of T cell subsets in relation to migration speed, and 
subsequent analysis using microfluidic droplet digital- PCR to match 
cell behaviors to RNA profiles. While yet to be realized, combining 
primary T cell culture and chemotactic studies with BBB models or in 
vitro myelination models, such as those previously described, could 
be used in future study of MS related disease mechanisms and po-
tential therapeutics.
5.5 | Brain cancer
Primary brain tumors refer to a heterogeneous group of tumors 
which originate within the CNS, ~75% of which are gliomas (Lapointe 
et al., 2018). While only accounting for ~3% of all new adult can-
cers, in children brain cancers are the most common form of solid 
tumors(Logun et al., 2018; Ostrom et al., 2014). Brain cancers lead to 
a high mortality rate and the unique microenvironment of the brain, 
particularly the restrictive nature of the BBB, make these cancers 
notoriously difficult to treat. MPS have already enabled some unique 
insights into the heterogeneous cell– cell and cell– environment inter-
actions that influence tumorigenicity, such as investigations by Lei 
et al demonstrating that nerve bundles can provide biophysical sup-
port for directional cancer cell migration (Lei et al., 2016).
An important benefit of MPS in cancer research is the ability to 
integrate patient- derived biopsies and tumor cells to provide direct 
translational relevance. By integrating bio- printing with on- chip cul-
ture, Yi et al. not only mimic heterotypic cellular interactions in a 
relevant brain- derived ECM 3D microenvironment with a hypoxic 
tumor core but also were able to reproduce clinically observed 
patient- specific resistances to chemoradiation and temozolomide 
using patient- derived cells (Yi et al., 2019). Future work might ad-
ditionally enable investigations of immune responses, potentially 
offering an advantage over current xenograft animal models, which 
require immune compromised animals.
The use of vascularized models has allowed the study of both 
anti- angiogenic and anti- cancer therapies (Sobrino et al., 2016) as 
well as in brain- specific models, for instance to assess strategies to 
enhance drug delivery through the BBB (Bonakdar et al., 2017) and 
to delineate pathways of brain metastasis. Indeed most malignant 
brain lesions are secondary brain tumors metastasized from other 
organs. With metastasis occurring in up to 30% of adults who have a 
malignant primary tumor at another site, with the highest incidence 
being in lung cancer (30%– 50% of patients) (Weller et al., 2015). A 
number of studies have made use of BBB MPS to model brain metas-
tasis, providing insights such as the role of astrocytes in restricting 
cancer cell extravasation (Xu et al., 2016). Such systems might in fu-
ture take advantage of establish panels of brain metastatic cell lines 
to investigate brain tropism and mechanisms that enable cancer cells 
to surmount the BBB (Valiente et al., 2020).
As is discussed in section 7.1 the ability to connect multiple MPS 
which mimic different tissue microenvironments opens up the op-
portunity to investigate organ– organ interactions and may be used 
to shed light on cancer metastasis. This approach has already been 
applied to lung– brain metastasis. Yi et al. demonstrate this through 
the connection of a lung on chip model incorporating flow and cy-
clic stretch, upstream of three separate organ specific 3D culture of 
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cells (Astrocytes, osteoblasts, and hepatocytes) demonstrating the 
importance of lung stromal cells on epithelial– mesenchymal transi-
tion and metastatic capacity (Yi et al., 2019).
For in depth reviews on how microfluidics models are not only 
advancing understanding of the brain tumor microenvironment 
but also cancer cell extravasation, diagnostics and drug efficacy 
screening see (Logun et al., 2018), (Cai et al., 2020), and (Coughlin 
& Kamm, 2020).
5.6 | Traumatic brain injury
Traumatic brain injury (TBI) is not only a leading cause of mortality 
and morbidity in adults but is also a risk factor for the future devel-
opment of neurodegenerative diseases such as AD and PD (Gupta & 
Sen, 2016). The initial mechanical shear, stretching, and compression, 
resulting from inertial forces induced during trauma such as motor 
vehicle accidents, falls, and sporting injuries, not only causes imme-
diate physical injury to brain tissue but also sets in motion a range 
of protracted structural and biochemical changes including; antero-
grade degeneration, mitochondrial dysfunction, and secondary in-
jury from excitotoxicity and inflammation (Yap et al., 2017). Recently 
CNS microfluidic models have been applied to TBI research to allow 
a more precise and targeted control of mechanical injury than can 
be produced in traditional in vitro models. A number of these devel-
opments have been made using neuronal cultures in axon guidance 
devices, taking advantage of high spatial precision to study axonal 
injury and white matter damage. One method to induce mechanical 
injury which has been used both in brain slices and with primary cell 
cultures, is by making use of flexible device materials (such as PDMS) 
and a pressurized pneumatic channel to deform the axonal channels 
mimicking the stretching of axons caused by shear deformation dur-
ing TBI (Dollé et al., 2013; Fournier et al., 2014; Yap et al., 2017). 
Other approaches such as vacuum aspiration (Taylor et al., 2005), 
chemical treatment, laser- based axotomy (Kim et al., 2009), and 
electro- mechanical shear in 3D cultures (LaPlaca et al., 2005) have 
all been explored and the benefits and limitations of each of these 
approaches have been reviewed elsewhere (Shrirao et al., 2018). 
While these systems provide reproducible and precise injury, they 
have yet to fully recapitulate the many pathogenic events that follow 
TBI, such as inflammatory responses and the corresponding swelling 
and tissue hypoxia. Instead the current benefit of current MPS in 
this case, is the ability to study a specific mechanism within precisely 
defined conditions.
6  | FUTURE DE VELOPMENT AND 
CHALLENGES
The desire in the pharmaceutical industry is to access models predic-
tive of target efficacy and drug safety and the dose of drug needed 
to achieve therapeutic benefit in the clinic. A lack of efficacy and 
safety are the two most significant reasons why drugs in clinical 
trials fail to progress (Harrison, 2016). Looking to the future, the 
hope is that new human CNS models in development, are better able 
to predict target efficacy and safety, compared to historically used 
models, reducing clinical attrition and late- stage failure.
In the past, targets have been identified using models as a start-
ing point, with a strong dependence on animal models. The pharma-
ceutical industry is now taking advantage of advances in genetics 
and computational biology, to interrogate large data sets from human 
populations, enabling target identification by linking genetic variants 
to human disease (Nelson et al., 2015), for example, LRRK2 to PD 
(Tolosa et al., 2020). The next step is target validation, to generate 
experimental evidence that therapeutic modulation of the target 
will provide efficacy in disease. A number of MPS now provide good 
candidates to manipulate a target in vitro with enhanced physiologi-
cal relevance, combined with the ability to perform multiparametric 
assessments of the consequences of target perturbation in longitu-
dinal studies. Integration of other technologies including real- time 
monitoring and iPSC technologies shows great promise in enhancing 
the utility of these systems. However, a number of challenges still 
remain, which hold back widespread adoption of these techniques, 
including issues with throughput, materials, robust validation, and 
standardization.
6.1 | Multi- organ systems
MPS are currently providing new insights into physiological and 
pathophysiological phenomena in the context of a specific functional 
unit of an organ or tissue, yet they fall short in modeling systemic 
responses and multi- organ interactions which typically necessi-
tate the use of animal models, such as in the study of the gut brain 
axis, brain cancer metastasis, and neuro- immune networks. There 
have been a number of efforts to link multiple MPS to mimic key 
organ– organ reciprocal actions and more ambitiously in “Body on 
Chip” projects, such as the $37 million Defense Advanced Research 
Projects Agency (DARPA) backed “Body on chip” project at the Wyss 
Institute for Biologically Inspired Engineering to integrate 10 human 
organ- on- chips. The MINERVA (MIcrobiota- Gut- BraiN EngineeRed 
platform to eVAluate intestinal microflora impact on brain function-
ality) project, funded by the European Research Council represents 
a specifically brain focused attempt to connect multiple microfluidic 
cultures (microbiota, gut epithelial barrier, immune cells, BBB, and 
brain) aiming to study the impact of intestinal microflora on neuro-
degeneration (Raimondi et al., 2019). A discussion of such programs 
is beyond the scope of this review, but Sung et al. provide a detailed 
analysis of how such ambitious large- scale projects may in future 
prove useful in delineating the contribution of organ– organ cross- 
talk in health and disease (Sung et al., 2019). While linking multiple 
MPS comes with a unique set of challenges along with significantly 
increased complexity and expense, specific interactions between 
defined functional units are already being used to provide physi-
ologically relevant insights, such as BBB- brain metabolic coupling 
(Maoz et al., 2018) and brain metastasis (Yi et al., 2019).
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6.2 | Incorporating iPSC technologies
Obtaining relevant human cells for CNS studies is particularly 
challenging, not only due to the scarcity of living tissue, (such as 
from epilepsy surgery) but also due to the post- mitotic nature 
of neurons, limiting their expansion in vitro. The ability to repro-
gram terminally differentiated somatic cells into stem cells by 
induced expression of pluripotency factors (OCT3/4, SOX2, c- 
Myc, Klf4) (Aasen et al., 2008; Takahashi et al., 2007; Takahashi 
& Yamanaka, 2006) has increased the availability of stem cells. 
Developmentally inspired protocols now allow the production of 
human brain cells which carry the unique genetic sequence of the 
adult somatic cell, thus enabling investigation of disease- specific 
phenotypes such as in Schizophrenia (Brennand & Gage, 2011; 
Brennand et al., 2015; Marchetto et al., 2011; Wen et al., 2014), 
Parkinson's (Sánchez- Danés et al., 2012), and Alzheimer's dis-
eases (di Domenico et al., 2019; Julia et al., 2019). The differ-
entiation of mature functional iPSC- derived cortical neurons is, 
however,, requires prolonged cultivation times, with maturation 
occurring over a period of months (Kirwan et al., 2015; Odawara 
et al., 2016), as neural progenitor cells differentiate into neu-
rons and astrocyte lineage cells, that participate in spontaneous 
network activity (Kirwan et al., 2015; Odawara et al., 2016; Shi 
et al., 2012). Single- cell RNA- seq data from human fetal and adult 
brain confirms that iPSC- derived cortical neurons are highly simi-
lar to primary cell neurons and with extended time in culture de-
velop a more adult phenotype (Handel et al., 2016). Protocols have 
also been established for derivation of specific neuronal identi-
ties including GABAergic (Yang et al., 2017), glutamatergic (Cao 
et al., 2017), and dopaminergic (Mahajani et al., 2019) neurons, 
while novel methods of rapid neuronal induction and maturation 
have also been developed by inducing lineage- determining tran-
scription factors (Yang et al., 2017). Methods for differentiating 
other key brain types including astrocytes (Lundin et al., 2018), 
microglia (Hasselmann & Blurton- Jones, 2020), and pericytes 
(Faal et al., 2019) have also been developed and many of these 
protocols have already been integrated into MPS (Appelt- Menzel 
et al., 2017; Prots et al., 2018; Usenovic et al., 2015). While in-
tegration of iPSC technologies may have the potential to greatly 
improve translational relevance for these models, as outlined in 
reviews by A. Sharma et al. (2020) and Pasteuning- Vuhman et al. 
(2020), to be widely adopted, they need to be carefully character-
ized both phenotypically and functionally. Without careful pheno-
typic characterization, cell identity of differentiated cells can be 
mistaken. This has been recently suggested in a preliminary report 
that provides single cell sequencing and immune- staining evi-
dence that a widely used brain endothelial differentiation strategy 
in fact produces neuroectodermal epithelial cells that form tight 
junctions reminiscent of those seen with BECs (Lu et al., 2019). 
Thus robust characterization and reliable methods are required 
for iPSC technologies to succeed in delivering on their potential 
to significantly improve CNS disease modeling.
6.3 | Advancing organoid models
Recent developments in 3D culturing of human iPSCs into neu-
ral “organoid” tissues offer a promising horizon to explore (Camp 
et al., 2015; Kelava & Lancaster, 2016; Pasca et al., 2015; Qian 
et al., 2016). Various region- specific brain organoids have already 
been described, including retinal, whole- brain, cortical, forebrain, 
and midbrain (Eiraku & Sasai, 2012; Eiraku et al., 2011; Kadoshima 
et al., 2013; Lancaster et al., 2013; Lindborg et al., 2016; Marton & 
Pasca, 2016; Pasca et al., 2015; Qian et al., 2016). Such organoid 
cultures show great promise to extend the possibilities of in vitro 
neurological research but are beyond the scope of this review (for 
reviews please see (Wang, 2018) and (Setia & Muotri, 2019)). One 
notable limitation of organoids is the lack of vascularization, leading 
to a necrotic core of cells at sizes above ~300 µm due to the limita-
tions of oxygen and nutrient diffusion. Combining organoid cultures 
with microfluidic techniques to provide perfusion (Yu et al., 2019) 
has shown to improve viability. Exploiting microfluidic techniques 
that promote angiogenesis to create perfusable vessels may allow 
further advances in organoid models (Shi et al., 2020). The use of 
microfluidic technologies is already advancing organoid culture, as 
reviewed by Park et al. (2019).
6.4 | Validation
One of the most important factors in the successful uptake of new 
in vitro models is validation and robust data showing improvements 
against existing models with greater relevance to the clinical disease. 
Emerging models are often described as “validated” by using existing 
drugs. This is valid for benchmarking new drugs against established 
drugs for safety and toxicology studies. In the search for novel drugs 
to address a large unmet need in neurological diseases, novel mecha-
nisms for which there is no benchmark drug are being explored. In 
this case it is important to understand the limitations of the model 
in terms of what aspects of healthy and disease tissue the model 
is able to recapitulate. For this, analysis of molecular markers and 
cellular morphology which can be compared to the clinical presenta-
tion of disease, would allow for direct comparison. This presents a 
challenge as many neurological disease markers remain to be stand-
ardized, often due to gaps in understanding the exact cellular and 
molecular underpinnings of human pathophysiology. Furthermore, 
while a great deal of insight has been gained from animal models of 
neurological disease, in many cases these fail to fully replicate the 
human disease. A recent paper by Donald Ingber raises the impor-
tant question of; given the mismatch between clinical data and in 
vivo models, whether a requirement of animal testing to confirm in 
vitro results for publication or grant funding still makes scientific or 
ethical sense (Ingber, 2020). The gold standard for comparison of 
disease models should always be the clinical disease itself, yet given 
the limited depth in which human pathophysiology can be studied, 
validation must be appropriately designed to match available data 
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and experimental possibilities. Where specific readouts in animal 
models are known to reflect human pathophysiological responses, 
intelligent and target comparisons can be made for validation of 
new models, not only comparing new models to the clinical data 
but also to established animal models. To ensure that experimen-
tal results are not artifactual manifestations of the cell culture en-
vironment, it would also be possible to create equivalent systems 
using animal cells to allow direct comparison with extensively char-
acterized in vivo models, as well as to the clinical and human tissue 
sample data. The results from initiatives such as the U.S. Food and 
Drug Administration's (FDA) Biomarker Qualification Program will 
likely improve the ease in which such comparisons between mod-
els and the real world disease can be made. The NIH Tissue Chips 
Consortium has brought together the Interagency Coordinating 
Committee on the Validation of Alternative Methods (ICCVAM) the 
National Center for Advancing Translational Sciences (NCATS) at 
the National Institutes of Health (NIH), DARPA and the FDA, and 
enabled the establishment of Tissue Chip Testing Centers in 2016 
and 2018 which allow for independent testing and validation of plat-
forms as part of a wider Tissue Chip Validation Framework.
6.5 | Materials
Plastic has been the material of choice for biologists for almost 
50 years and as such biologists are familiar with the capabilities. 
Some microfluidic devices manufacturers have opted for the use 
of thermoplastics, while in other cases limitations in machining and 
properties have necessitated the use of other less familiar materials. 
The vast majority of microfluidic laboratories experimenting with 
new possibilities through rapid prototyping use PDMS due to its 
ease of fabrication, low cost production, optical clarity, gas perme-
ability, and relative biocompatibility. PDMS is also used for its high 
elasticity, as in the Emulate Chip which enables stretch to be used 
to mimic breathing cycles (Huh, 2015) and vascular stretch (Sato 
et al., 2019). PDMS is, however, highly hydrophobic with a low sur-
face energy that, unless treated, resists biological coatings and may 
also absorb small molecules such as drugs, which can have signifi-
cant impacts on detection of analytes and drug bioavailability (van 
Meer et al., 2017). Many commercial MPS are returning to the use of 
thermoplastics, where flexibility is not a requirement, while others 
are investigating novel materials with potentially superior character-
istics, such as thiol- based chemistries (Ostemers) (Zhou et al., 2017). 
For an in- depth review of materials for microfluidic chip fabrication, 
see Ren et al. (2013).
6.6 | Increasing data through integration of real- 
time monitoring
Multi- parametric sensing is highly desirable, to generate high- 
content data from cell systems. In this context, the extensive de-
velopments on electrochemical enzymatic sensing of glucose and 
lactate, primarily in the field of blood sugar monitoring for diabet-
ics, are now being applied to MPS and would be a useful addition 
to CNS models. Indeed glucose and lactate production, along with 
CO2 production and O2 consumption yield a detailed picture of cell 
metabolism, and have been incorporated into MPS to monitor cell 
growth (Prill et al., 2014). Oxygen and glucose consumption has been 
usefully linked to neuronal firing and can even predict burst activity 
such as that seen in epileptic seizures (Ivanov et al., 2015). pH sensing 
may also be useful, which in many cases is a substitute for monitor-
ing lactic acid production. Functionalization of electrodes with redox 
enzymes or other suitable biorecognition elements, can in principal 
allow sensing of a wide variety of analytes, although requiring care-
ful design of the functionalization strategy and materials/reagents.
A major challenge in integration of sensing technology comes 
when the cell systems become more 3D to provide a more natu-
ral environment for the cells. In terms of electrodes, currently, the 
majority of systems rely on flat, rigid electrodes. New technologies 
are nevertheless enabling flexible polymeric devices which can be 
tailored to adapt to tissues in a more seamless manner (Kalmykov 
et al., 2019; Pitsalidis et al., 2018). Much of this development is being 
pushed by the neural interfacing community, faced with the size-
able challenge of implanting electrodes into brain tissue for dura-
ble and non- invasive neuronal recording. Lessons learnt from this 
community will inevitably translate into better electrical recording 
devices in vitro, adapted to complex biology. Transparency of the 
next- generation electronic materials translates into an added advan-
tage in vitro, in terms of imaging cells in devices (Curto et al., 2017). 
Overall, the advantages obtained by electrophysiological and real- 
time monitoring systems are compensated by higher costs and by the 
increased complexity of fluidically sealing the microfluidic device.
6.7 | Increasing throughput and 
integrating automation
The throughput of models for the lead discovery can range from 
1000s for antibody screening to 100,000, even 1,000,000s, for a 
small molecule screen. Small molecules are the most likely modal-
ity for CNS diseases, in which an important hurdle to overcome is 
drug delivery across the BBB. Novel BBB models, if appropriately 
scaled, could aid in assessing the bioavailability of a drug in the 
lead optimization phase, where typically the numbers of drugs pro-
filed through a cell- based model is in the range of hundreds. This 
is within the range that could be accommodated using multi- device 
platforms such as the OrganoPlate® from Mimetas (96 two chan-
nel or 40 three channel devices in a 384- well plate format) (Wevers 
et al., 2016), the IMPACT Platform from Noo Li Jeon's laboratory 
(S.- R. Lee et al., 2019; S. Lee et al., 2019) (12 devices in a microscope 
slide footprint or 96 devices on a 96- well plate format) or the plat-
form presented by Phan et al. (2017) (12 devices in a 96- well plate 
format), all of which provide patterning of hydrogels for culture of 
multiple cell types with flanking perfusion channels supplied with 
flow by passive hydrostatic head. Fantuzzo et al. have also taken the 
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concept of axon guidance first presented by Taylor et al. and de-
veloped a high- throughput arrayed neural circuitry platform with 96 
devices per plate (Fantuzzo et al., 2020), while Parrish et al., 2018, 
have taken a membrane- based dual perfusion chamber approach 
to provide a 96- well microplate platform amenable for BBB studies 
(Parrish et al., 2018). This last example and many other MPS models 
require complex bespoke perfusion systems and holders to operate 
the devices, which may limit up take or restrict the user to a sin-
gle type of MPS, thus raising the issue of standardization within the 
field.
6.8 | Standardization
Standardization of microfluidic neurological models, and microfluidics 
in general presents a huge challenge, due to the inherently interdis-
ciplinary nature of the field and the fast moving pace of innovation. 
Failure to standardize may have massive implications to the growth 
of the field and widespread uptake of emerging technologies, how-
ever, poorly devised standards could stifle innovation and techno-
logical optimization (Blind, 2016). Within other technology fields 
standards have previously arisen due to dominant commercial entities 
or from collectives and regulatory bodies (such as the International 
Organization for Standardization and the Institute of Electrical and 
Electronics Engineers). The microfluidics and Organ- on- chip fields are 
currently dominated by small biotech start- ups and academic groups. 
It would seem that standards are most likely emerge from discus-
sions between Organ- on- chip communities and cross- disciplinary 
consortia such as ORCHID (Organ- on- Chip Development DMT), 
European Organ- on- Chip Society (EUROoCS), the Organ- on- a- 
Chip Technologies Network in the UK and the NIH Tissue Chips 
Consortium in the United States. Such networks provide platforms 
for discussion between academic and industry developers, pharma-
ceutical and research institute end users, and funding agencies and 
regulatory bodies to develop standardization strategy. Within the 
pharmaceutical industry, significant interest in MPS has led to the for-
mation of the IQ MicrophysiologicalSystems Affiliate, a collaboration 
of over 20 pharmaceutical and biotechnologies companies including 
AbbVie, AstraZeneca, BMS, GSK, Eli Lilly, Merck, Novartis, and Pfizer. 
This cross- pharma collaboration, created to facilitate data sharing and 
expedite uptake and impact of MPS, will also likely have an impact on 
how MPS and Organ- on- Chip technologies are standardized.
Standards that emerge will likely exist on multiple levels, reflect-
ing the multidisciplinary nature of the field, and may include: fluidic 
and electrical interconnects, dimensions, materials, media, flow rates 
and cells, and culture protocols. Any standards that emerge should, 
and often do, follow currently accepted bioscience and pharma-
ceutical industry standards such as glass slide standard dimensions 
(Emulate chips and IBIDI channel slides), ANSI/SLAS multi- well plate 
footprint (The OrganoPlate® from Mimentas and CellASIC® ONIX 
Microfluidic Plates from Merck), and the Luer Lock interface (IBIDI 
channel slides). Increasing standardization from the Organ- on- chip, 
microfluidic community must not stifle creativity and innovation but 
improve compatibility to facilitate and simplify collaboration and in-
tegration, accelerating innovation, and widespread adoption.
7  | CONCLUSIONS AND CONSIDER ATIONS 
FOR E ARLY ADOPTERS
As we have detailed in this review, MPS have provided an array of 
new opportunities to study neurological disease and new technolo-
gies are rapidly developing. The initial foray into microfluidic tech-
nologies for disease modeling has been spearheaded through close 
collaborations between engineers, chemists, and biologists, and 
while many of these pioneers are now offering expertise in their 
platform as outsourced research and disease modeling services 
(such as Aracari Biosciences Inc. and Hesperos Inc.), a number of 
devices have already entered the market targeting biologists as end 
users (Table 1) and some even offer custom device fabrication ser-
vices (e.g., TissUse GmbH and uFluidic). While commercially avail-
able systems often come with SOPs and troubleshooting guides 
specific to the platform, early adopters should be aware of a number 
of unique challenges with using microfluidic devices.
With microfluidic devices containing 10s to thousands of cells 
rather than the millions of cells used in macroscale cultures, par-
ticular attention should be made to seeding densities and even dis-
tribution of cells. Cell clumps can easily block microfluidic devices 
or result in abnormal distribution and growth of cells. At the small 
scales of MPS, evaporation can have a large effect on volumes of cell 
culture, and particular care should be made to maintain high humid-
ity. Scaling also influences surface area to volume ratio. Traditional 
macroscale cultures typically have a very low surface area to volume 
ratio when compared to MPS. For instance in the example by Walker 
and Beebe, a 35 – mm- tissue culture dish may have surface area to 
volume ratio of 11 cm−1 while a typical microchannel may have a 
surface area to volume ratio of 800 cm−1. MPS show rapid exchange 
of gases and enable study of autocrine and paracrine signaling with-
out the significant dilutions that occur in macroscale cultures. On 
the other hand, nutrient depletion and waste build- up is rapid in 
the absence of flow (as is the case in vivo). As such, the concepts 
of effective culture volume and a critical perfusion rate introduced 
by Walker and Beebe (Walker et al., 2004; Young & Beebe, 2010) 
should be well understood, along with an appreciation of the effects 
of the resulting shear and the implications that the high surface area 
to volume ratio and material properties have on the microenviron-
ment. For instance, in case of PDMS devices, surface adsorption of 
hydrophobic dyes and drug molecules or bulk absorption of nutri-
ents from media can confound results and while high gas permeabil-
ity allows rapid O2 exchange, water vapor permeability can result in 
changes in concentration of media constituents unless high humid-
ity is maintained. Thus appropriate coatings or pre- incubation with 
media or serum to saturate absorption prior to cell culture, should 
be considered.
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Shear stress can be used to enhance barrier functions of BBB 
models and increase phenotypic relevance of endothelial cells. 
However it should be noted that shear can easily be introduced 
where it is not intended, such as neuronal cultures, which can be 
highly sensitive to shear. As an example, a hydrostatic head of 
10 mm feeding a channel of 100 μm high 500 μm wide and 10 mm 
long can introduce brief shear stress of over 2 dyne/cm2, while in 
vivo shear of cells in contact with cerebrospinal fluid is approxi-
mately 0.01 dyne/cm2 with small increases having previously been 
shown to influence cell behavior (Park et al., 2017). A background 
knowledge and appreciation of fluid dynamics would benefit those 
adopting such studies. Furthermore, new users of MPS should care-
fully consider the limitations and challenges specific to the platform 
they intend to use when designing experiments. Examples of these 
considerations include; compatibility with desired readouts, such 
as fluorescent imaging, whether enough biological material can be 
harvested for the analysis of choice and compatibility of existing 
cell culture protocols, for example, surface coating, along with the 
potential increase in costs and extra instrumentation that may be 
required.
Given that many biological laboratories are already taking advan-
tage of the unique experimental possibilities provided by MPS, these 
systems, especially when integrated with advances in stem cell tech-
nologies and real- time monitoring, show great potential in enhancing 
the predictive power of pre- clinical studies through integration as 
part of the drug discovery pipeline.
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